FORTIS C-DOC
B-16, Chirag Enclave, Opposite, Nehru Place, Delhi
Clinic- H-11 Sec-25 Jalvayu Vihar, noida
Mobile- 09818249682
Professional Experience
> Presently Consultant:Additional Director at Fortis C-DOC Centre of Excellence for Diabetes, Metabolic Diseases and
Endocrinology,Delhi.
> Formerly Consultant :Head Clinical Operations and Senior Consultant at Fortis C-DOC Centre of Excellence for Diabetes,
Metabolic Diseases and Endocrinology,Delhi
> Formerly Consultant :Consultant in the Department of Diabetes and Metabolic Disease at Fortis Flt Lt Rajan Dhall Hospital,
Vasant Kunj,Delhi
> Formerly Consultant :Consultant in Internal Medicine at Apollo Clinic, Noida (India), an initiative of Apollo Health and Lifestyle
Limited
> Formerly Consultant : Senior Resident in the Department of Cardiology and as Internist at Escorts Heart Institute and Research
Centre,Delhi
> Formerly Consultant : Senior Resident (Registrar) in the Department of Medicine at All India Institute of Medical Sciences,Delhi.
Research
Clinical Trial: A phase II, 12-week randomised, double blind, parallel group placebo-controlled study to evaluate safety, tolerability, and efficacy of GRC 8200, a new oral DPP-IV inhibitor, in patients with Type 2 Diabetes Mellitus.
Clinical Trial: Co-investigator in the trial titled “A multi-centre, randomised, double blind, placebo-controlled clinical trial to evaluate the effect of 52 weeks treatment with Vildagliptin on left ventricular function in patients with Type 2 Diabetes and congestive heart failure. [Co-Investigator]
Clinical Trial: A randomised, double-blind, placebo- and Sitagliptin-controlled, multi-centre study to evaluate safety and efficacy of Dutogliptin in Type 2 Diabetes Mellitus subjects with moderate and severe renal impairment including subjects on Hemodialysis. [Co-Investigator]
Clinical Trial: A 12-week multi-centre, randomised, double blind, placebo-controlled parallel group adaptive design study to evaluate the efficacy on Blood Glucose Control and safety of five doses of LCQ 908 (2, 5, 10, 15 & 20 mg) or Sitagliptin 100mg on a background therapy of Metformin in obese patients with Type 2 Diabetes. [Co-Investigator]
Clinical Trial: A multi-centre, randomised, double-blind, placebo-controlled Phase IV trial to evaluate the effect of Saxagliptin on the incidence of Cardiovascular death,Myocardial Infarction or Ischemic Stroke in patients with Type 2 Diabetes Mellitus. [Co-Investigator]